Loading…
Chinese biopharma that in-licenses innovative drugs in nephrology, infectious disease and oncology for Greater China/Asia.
Chinese biopharma that in-licenses innovative drugs in nephrology, infectious disease and oncology for Greater China/Asia.
Pays licensors upfront fees, milestones and royalties for Greater China and some Asian rights, then earns from selling the drugs itself to hospitals, with Nefecon, a kidney-disease drug licensed from Calliditas, as the lead product. Each market's approvals and reimbursement listings set the volumes.
In one line: A Chinese in-licensing specialty pharma, similar to a smaller Zai Lab.
Moat: narrow (regulatory licence, distribution). Regional development and commercialization rights secured via licensing deals with global biotechs.
Headquarters: Shanghai, China · Founded: 2017 · Employees: 812
Size Everest Medicines (1952.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.22B, the 545th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$27.02 on 6 Nov 2026.
Performance Over six months the shares fell 20.0%, against -6.0% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 192.6% over the last twelve months (peer median -1.5%); the operating margin is -5.3% (peer median 4.5%).
Valuation It trades at 26.9× forward earnings against a peer median of 19.6× (3rd most expensive of 10).
Capital Return on invested capital runs 16.1 points below its cost of capital (14.1% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$2.69B | HK$1.85B | HK$766M | HK$139M | HK$14.9M |
| Revenue growth | — | +142% | +451% | +835% | — |
| Gross profit | HK$1.69B | HK$1.11B | HK$426M | HK$16.3M | -HK$40.3M |
| EBITDA | HK$40.7M | -HK$249M | -HK$681M | -HK$849M | -HK$1.58B |
| Net income | -HK$59.3M | -HK$323M | -HK$1.13B | -HK$933M | -HK$288M |
| Free cash flow | -HK$354M | -HK$192M | -HK$829M | -HK$988M | -HK$1.76B |
| Capital expenditure | HK$892M | HK$378M | HK$221M | HK$294M | HK$503M |
| Total debt | n/a | HK$1.03B | HK$612M | HK$593M | HK$124M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Everest Medicines 1952.HK | $1.22B | -20% | +193% | -5% | 26.9× | n/a |
| Sunshine Lake Pharma 6887.HK | $2.85B | -9% | +20% | -3% | n/a | n/a |
| China Medical System 0867.HK | $3.30B | -16% | +15% | 20% | 10.9× | 2.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1952.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.0% | -2.4% | 10th lowest of 21 |
| 6-month return | -20.0% | -6.0% | 7th lowest of 21 |
| Distance from 52-week high | -47.2% | -31.2% | 7th lowest of 21 |
| Revenue growth (TTM) | +192.6% | -1.5% | highest of 16 |
| Operating margin | -5.3% | 4.5% | 7th lowest of 17 |
| Forward P/E | 26.9× | 19.6× | 3rd most expensive of 10 |
| ROIC minus cost of capital | -16.1 pp | -3.3 pp | 8th lowest of 19 |
| Net debt / EBITDA | -1.3× | 1.3× | 2nd least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 26.9× | n/a | n/a |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 7.7× | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.21B | +50% | +1% | 16% | 8.9× | 3.3% | +15.5% |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.21B | -8% | -2% | 15% | 19.6× | 4.5% | -1.2% |
| Jiuzhitang 000989.SZ | China | $1.19B | -13% | +46% | 19% | 22.7× | -3.7% | -9.0% |
| MannKind MNKD | United States | $1.25B | +11% | +30% | 3% | n/a | n/a | n/a |
| InventisBio 688382.SS | China | $1.19B | -41% | -61% | -563% | n/a | 10.4% | -60.6% |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.26B | -57% | +81% | -305% | n/a | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.27B | -29% | +14% | 11% | n/a | 11.7% | +18.1% |
| GC Biopharma 006280.KS | South Korea | $1.18B | +2% | -3% | 4% | 5.0× | 8.3% | +5.8% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.18B | -4% | -9% | 11% | 19.6× | 5.8% | +11.3% |
| Nektar Therapeutics NKTR | United States | $1.27B | -54% | -27% | -239% | n/a | n/a | n/a |
| Vetoquinol VETO.PA | France | $1.17B | +22% | -1% | 15% | 15.8× | -3.0% | +4.2% |
| Cosmo CMHC.SW | Switzerland | $1.17B | -25% | -45% | -13% | 432.6× | n/a | n/a |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1.17B | +28% | +24% | 6% | 85.2× | 16.2% | +19.4% |
| North China Pharmaceutical 600812.SS | China | $1.17B | -8% | -21% | 5% | n/a | 1.4% | -4.2% |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | n/a | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |